Skip to main content
Cancer Explained
Donate
Beginner 5 min readEditorial review complete

Erbitux (Cetuximab): What It Is and What to Expect

Erbitux (Cetuximab) is a targeted therapy called a monoclonal antibody used to help treat some colorectal cancers and head and neck cancers.

NCI source

National Cancer Institute — Cetuximab

A woman laughs with a nurse during an infusion, IV line visible
A woman laughs with a nurse during an infusion, IV line visible

Key fact

Erbitux is the brand name; its generic name is cetuximab.

The short answer

Erbitux (Cetuximab) is a targeted therapy called a monoclonal antibody. It attaches to a protein called EGFR on some cancer cells and blocks a signal that tells them to grow. It is used to help treat some colorectal cancers and head and neck cancers, and is usually given as an IV infusion. Like all cancer medicines it can cause side effects; this page explains the common ones and the warning signs to report. It is educational only and not a substitute for your care team's advice.

  • Erbitux is the brand name; its generic name is cetuximab.

  • It is a targeted therapy called a monoclonal antibody — it attaches to a protein called EGFR on some cancer cells and blocks a signal that tells them to grow.

  • It is used to help treat some colorectal cancers and head and neck cancers.

  • It is usually given as an IV infusion.

Choose how you want to understand this

The full explanation.

A gene test comes before the first dose

Erbitux is the brand name. Cetuximab is the generic name. It is an antibody that plugs EGFR, a receptor on the cell surface that tells cells to divide.

In bowel cancer this only works if the RAS genes in the tumor are unchanged. If the tumor carries a RAS mutation, the drug does not help. The label goes further and says these patients did worse. So the approved use is limited to KRAS wild-type, EGFR-expressing bowel cancer that has spread, confirmed with an FDA-approved test. The label states plainly that cetuximab is not for RAS-mutant bowel cancer, and not for cases where the RAS result is unknown. Ask to see your own result before the first dose.

The cancers it is approved to treat

For squamous cell cancer of the head and neck there are three settings. With radiation, for disease that is locally or regionally advanced. With platinum chemotherapy and fluorouracil, as first treatment when the cancer has come back or spread. On its own, after platinum treatment has stopped working.

For bowel cancer that has spread and has unchanged KRAS, there are also three. With FOLFIRI as first treatment. With irinotecan when irinotecan-based chemotherapy has stopped working. On its own after both oxaliplatin- and irinotecan-based chemotherapy have failed, or when irinotecan cannot be tolerated.

A separate approval covers bowel cancer with a BRAF V600E mutation, given with encorafenib after earlier treatment.

The boxed warning: reactions and cardiac arrest

Two things sit in the boxed warning.

Infusion reactions. These occurred in 8.4% of 1,373 people across trials, and were severe in 2.2%. They can be fatal. Most arrive with the first infusion. That is why an antihistamine is given first and why you are watched during the drip and afterwards. Speak up at once about flushing, hives, a tight throat, wheeze, dizziness, or a feeling that something is badly wrong.

Cardiopulmonary arrest. Sudden death has happened in people with head and neck cancer given cetuximab with radiation, or with platinum chemotherapy and fluorouracil. The label asks for magnesium, potassium and calcium to be watched during treatment and after it.

The rash that most people get

An acne-like rash on the face, scalp, chest and back is the signature effect. Skin dries and cracks. The skin around fingernails and toenails can become inflamed and infected. Broken skin can let serious infections in. Sunlight makes it worse, so cover up and use sunscreen.

Your team can prescribe treatment for it. Do not reach for ordinary acne products without asking, because this is not acne and some of them make it worse.

Magnesium, and the blood tests that follow it

Low magnesium occurred in 55% of 365 people in the trials the label cites, and was severe in 6% to 17%. It can start days to months after treatment begins, which is why the label asks for weekly checks during treatment and for at least 8 weeks after the last dose. When magnesium falls, calcium and potassium often follow. Cramps, twitching, an odd heartbeat or unusual weakness are all worth reporting. Replacement is usually given by drip.

Questions to raise before you start

  • What is my tumor's RAS result, and which test was used?
  • Will I have cetuximab with radiation, with chemotherapy, or on its own?
  • How often will my magnesium be checked?
  • What should I put on my skin from day one, rather than waiting for the rash?
  • Who do I call if a reaction starts after I get home?

When to get help sooner

  • Call 911 or go to an emergency department if your throat tightens, you wheeze, your face or lips swell, or you feel suddenly and badly unwell after an infusion. Reactions can be fatal, and some begin after you have gone home. Chest pain, collapse or a pounding irregular heartbeat needs the same response, given the cardiac arrest warning on this label.
  • Call your care team the same day if the rash blisters, weeps or spreads over a wide area, or the skin beside a fingernail or toenail turns red, hot and swollen. Broken skin here is a route in for serious infection.
  • Call your care team within a day or two if you get muscle cramps, twitching, odd heart flutters or unusual weakness. These can mean magnesium has dropped, which happened in over half the people in the trials the label cites, and can start days to months after treatment begins.

Sources

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9

https://www.cancer.gov/about-cancer/treatment/drugs/cetuximab

Words to know

Tap any term to see what it means.

Browse the full glossary →

An older woman and female clinician look over medication bottles, smiling

Common questions

What is Erbitux?

Erbitux (Cetuximab) is a targeted therapy called a monoclonal antibody. It attaches to a protein called EGFR on some cancer cells and blocks a signal that tells them to grow. It is used to help treat some colorectal cancers and head and neck cancers.

How is Erbitux given?

It is usually given as an IV infusion. It is given as an intravenous (IV) infusion — a slow drip into a vein — at a clinic or hospital, usually repeated on a schedule of cycles with rest periods in between. The exact schedule is set by your care team.

What are the common side effects of Erbitux?

Commonly reported side effects include acne-like skin rash, tiredness, diarrhea, low magnesium, and nail changes. Not everyone gets them, and many can be managed. Tell your care team about anything new or worsening.

Does Erbitux cure cancer?

That depends on the person, the cancer type, and its stage. For some people a medicine like this can control cancer for a long time or be part of a curative plan; for others the goal is to slow the cancer or ease symptoms. Your care team can explain the goal in your situation.

Questions to ask your doctor

Being prepared helps you get the most out of your appointments. Save or print these questions.

Open my question list

Tap a question to save it to your list (kept on this device).

Human Connection Layer

Speak With Trained Specialists & Human Navigators

Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.

Free & Confidential

Talk to a trained cancer information specialist

Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.

Contact your oncology team

Locate after-hours contact numbers, portal messages, or urgent triage phone lines.

Find a patient navigator

Get one-on-one help with appointments, logistics, translation, and care coordination.

Find a genetic counselor

Discuss inherited mutation risk, family history, and genetic testing options.

Find an oncology social worker

Access emotional counseling, family support groups, and mental health resources.

Find a financial navigator

Locate copay assistance foundations, grant programs, and lodging/travel support.

Find a clinical-trial specialist

Search matching studies and speak with NCI trial information specialists.

Get urgent help

Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.

Help Us Improve This Guide

Did this explanation answer your question and help you determine your next step?

Know someone who needs this?

Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.

Email itText itWhatsApp

Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.

Knowledge Check

0 of 2 answered

  1. Q1.What kind of medicine is Erbitux?
  2. Q2.Which of these is Erbitux used to help treat?

This self-assessment checks understanding of educational content only. It is not medical advice.

Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.

Sources last checked: 2026-07-14 what this meansLast updated: 2026-08-17Next planned review: 2027-01-14

How this page was created

Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.

Editorial status — Editorial review complete. This page completed Cancer Explained's editorial checks (sources, safety, plain language, duplication). It has not been reviewed by a physician or other healthcare professional.

General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.

Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.

Our editorial processHow we use AIReport an error

How this page was created

Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.

Editorial status: Editorial review complete This page completed Cancer Explained's editorial checks (sources, safety, plain language, duplication). It has not been reviewed by a physician or other healthcare professional.

Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.

Read more about our editorial process, our use of AI, and our corrections policy.

Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.

After using this page, do you understand what to do next?

Anonymous — we only record the answer, never who gave it.

Related learning map

How this explanation connects to 12 other things you can explore — related topics, terms, questions, practice, and its NCI source.

Erbitux (Cetuximab): What It Is and What to Expect